Replicate Bioscience
Replicate Bioscience leverages next-generation self-replicating RNA (srRNA) vectors to advance treatments in infectious disease, oncology, and autoimmune disorders.
Company Overview
Replicate Bioscience is a biotechnology company focusing on next-generation self-replicating RNA (srRNA) vectors. The company aims to deliver outsized protein expression and durable therapeutic effects through its proprietary platform. They are advancing a robust pipeline of srRNA treatments intended for various therapeutic areas, including infectious disease, oncology, and autoimmune disorders.
srRNA Technology
Replicate Bioscience's core technology leverages self-replicating RNA vectors to achieve approximately a 1000-fold expression gain over linear mRNA and a 100-fold gain over standard srRNA. This higher expression level aims to produce more robust and sustained therapeutic effects. The platform includes end-to-end integration for optimizing gene inserts, identifying suitable srRNA vectors, and selecting delivery systems tailored to each medical indication.
Therapeutic Areas
The company is developing treatments targeting various therapeutic areas such as oncology, infectious diseases, and autoimmune disorders. Their library of viral vectors is selected for robust and sustainable protein expression, ensuring the long-term effectiveness of the treatments. This approach aims to address the unmet medical needs in these critical health sectors.
Platform Capabilities
Replicate Bioscience’s platform capabilities include a comprehensive approach to integrating gene inserts into self-replicating RNA vectors. The platform also facilitates the identification of suitable vectors and optimizes the selection of delivery systems for each specific indication. This holistic approach ensures enhanced performance and efficacy of their srRNA-based therapies.
